This HTML5 document contains 280 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n24http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n32http://linked.opendata.cz/resource/drugbank/drug/DB00620/identifier/wikipedia/
n25http://linked.opendata.cz/resource/drugbank/dosage/
n33http://linked.opendata.cz/resource/drugbank/drug/DB00620/identifier/pharmgkb/
n4http://linked.opendata.cz/resource/drugbank/mixture/
n27http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB00620/identifier/pubchem-compound/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00620/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n30http://www.rxlist.com/cgi/generic/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00620/identifier/kegg-drug/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00620/identifier/drugbank/
n29http://linked.opendata.cz/resource/drugbank/patent/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00620/identifier/iuphar/
n28http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00620/identifier/guide-to-pharmacology/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/medicinal-product/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00620/identifier/national-drug-code-directory/
n23http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n12http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/property/
n31http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00620/identifier/chemspider/
n10http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00620
rdf:type
n3:Drug
n3:description
A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739)
n3:dosage
n25:271B583F-363D-11E5-9242-09173F13E4C5 n25:271B5840-363D-11E5-9242-09173F13E4C5 n25:271B5841-363D-11E5-9242-09173F13E4C5 n25:271B5842-363D-11E5-9242-09173F13E4C5 n25:271B583B-363D-11E5-9242-09173F13E4C5 n25:271B583C-363D-11E5-9242-09173F13E4C5 n25:271B583D-363D-11E5-9242-09173F13E4C5 n25:271B583E-363D-11E5-9242-09173F13E4C5 n25:271B5837-363D-11E5-9242-09173F13E4C5 n25:271B5838-363D-11E5-9242-09173F13E4C5 n25:271B5839-363D-11E5-9242-09173F13E4C5 n25:271B583A-363D-11E5-9242-09173F13E4C5 n25:271B5834-363D-11E5-9242-09173F13E4C5 n25:271B5835-363D-11E5-9242-09173F13E4C5 n25:271B5836-363D-11E5-9242-09173F13E4C5 n25:271B584B-363D-11E5-9242-09173F13E4C5 n25:271B584C-363D-11E5-9242-09173F13E4C5 n25:271B5847-363D-11E5-9242-09173F13E4C5 n25:271B5848-363D-11E5-9242-09173F13E4C5 n25:271B5849-363D-11E5-9242-09173F13E4C5 n25:271B584A-363D-11E5-9242-09173F13E4C5 n25:271B5843-363D-11E5-9242-09173F13E4C5 n25:271B5844-363D-11E5-9242-09173F13E4C5 n25:271B5845-363D-11E5-9242-09173F13E4C5 n25:271B5846-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
88 minutes
n3:indication
For the treatment of perennial and seasonal allergic rhinitis.
n3:manufacturer
n5:271B5803-363D-11E5-9242-09173F13E4C5 n5:271B5804-363D-11E5-9242-09173F13E4C5 n5:271B5807-363D-11E5-9242-09173F13E4C5 n5:271B5805-363D-11E5-9242-09173F13E4C5 n5:271B5806-363D-11E5-9242-09173F13E4C5 n5:271B57E9-363D-11E5-9242-09173F13E4C5 n5:271B57EA-363D-11E5-9242-09173F13E4C5 n5:271B57E7-363D-11E5-9242-09173F13E4C5 n5:271B57E8-363D-11E5-9242-09173F13E4C5 n5:271B57F0-363D-11E5-9242-09173F13E4C5 n5:271B57F1-363D-11E5-9242-09173F13E4C5 n5:271B57EB-363D-11E5-9242-09173F13E4C5 n5:271B57EC-363D-11E5-9242-09173F13E4C5 n5:271B57E1-363D-11E5-9242-09173F13E4C5 n5:271B57E2-363D-11E5-9242-09173F13E4C5 n5:271B57DF-363D-11E5-9242-09173F13E4C5 n5:271B57E0-363D-11E5-9242-09173F13E4C5 n5:271B57E5-363D-11E5-9242-09173F13E4C5 n5:271B57E6-363D-11E5-9242-09173F13E4C5 n5:271B57E3-363D-11E5-9242-09173F13E4C5 n5:271B57E4-363D-11E5-9242-09173F13E4C5 n5:271B57DE-363D-11E5-9242-09173F13E4C5 n5:271B5802-363D-11E5-9242-09173F13E4C5 n5:271B57FC-363D-11E5-9242-09173F13E4C5 n5:271B57FD-363D-11E5-9242-09173F13E4C5 n5:271B57FA-363D-11E5-9242-09173F13E4C5 n5:271B57FB-363D-11E5-9242-09173F13E4C5 n5:271B5800-363D-11E5-9242-09173F13E4C5 n5:271B5801-363D-11E5-9242-09173F13E4C5 n5:271B57FE-363D-11E5-9242-09173F13E4C5 n5:271B57FF-363D-11E5-9242-09173F13E4C5 n5:271B57F4-363D-11E5-9242-09173F13E4C5 n5:271B57F5-363D-11E5-9242-09173F13E4C5 n5:271B57F2-363D-11E5-9242-09173F13E4C5 n5:271B57F3-363D-11E5-9242-09173F13E4C5 n5:271B57F8-363D-11E5-9242-09173F13E4C5 n5:271B57F9-363D-11E5-9242-09173F13E4C5 n5:271B57F6-363D-11E5-9242-09173F13E4C5 n5:271B57F7-363D-11E5-9242-09173F13E4C5 n5:271B57ED-363D-11E5-9242-09173F13E4C5 n5:271B57EE-363D-11E5-9242-09173F13E4C5 n5:271B57EF-363D-11E5-9242-09173F13E4C5
owl:sameAs
n27:DB00620 n28:DB00620
dcterms:title
Triamcinolone
adms:identifier
n14:31307 n15:D00385 n16:0781-3243-75 n17:46507950 n18:29046 n19:2870 n21:2870 n22:DB00620 n32:Triamcinolone n33:PA451749
n3:mechanismOfAction
The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Firstly, however, these glucocorticoids bind to the glucocorticoid receptors which translocate into the nucleus and bind DNA (GRE) and change genetic expression both positively and negatively. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
n3:packager
n5:271B57B8-363D-11E5-9242-09173F13E4C5 n5:271B57C5-363D-11E5-9242-09173F13E4C5 n5:271B57C6-363D-11E5-9242-09173F13E4C5 n5:271B57C3-363D-11E5-9242-09173F13E4C5 n5:271B57C4-363D-11E5-9242-09173F13E4C5 n5:271B57C1-363D-11E5-9242-09173F13E4C5 n5:271B57C2-363D-11E5-9242-09173F13E4C5 n5:271B57BF-363D-11E5-9242-09173F13E4C5 n5:271B57C0-363D-11E5-9242-09173F13E4C5 n5:271B57CB-363D-11E5-9242-09173F13E4C5 n5:271B57CC-363D-11E5-9242-09173F13E4C5 n5:271B57C9-363D-11E5-9242-09173F13E4C5 n5:271B57CA-363D-11E5-9242-09173F13E4C5 n5:271B57C7-363D-11E5-9242-09173F13E4C5 n5:271B57C8-363D-11E5-9242-09173F13E4C5 n5:271B579D-363D-11E5-9242-09173F13E4C5 n5:271B579E-363D-11E5-9242-09173F13E4C5 n5:271B579B-363D-11E5-9242-09173F13E4C5 n5:271B579C-363D-11E5-9242-09173F13E4C5 n5:271B579A-363D-11E5-9242-09173F13E4C5 n5:271B57D5-363D-11E5-9242-09173F13E4C5 n5:271B57D6-363D-11E5-9242-09173F13E4C5 n5:271B57D3-363D-11E5-9242-09173F13E4C5 n5:271B57D4-363D-11E5-9242-09173F13E4C5 n5:271B57D1-363D-11E5-9242-09173F13E4C5 n5:271B57D2-363D-11E5-9242-09173F13E4C5 n5:271B57CF-363D-11E5-9242-09173F13E4C5 n5:271B57D0-363D-11E5-9242-09173F13E4C5 n5:271B57DD-363D-11E5-9242-09173F13E4C5 n5:271B57DB-363D-11E5-9242-09173F13E4C5 n5:271B57DC-363D-11E5-9242-09173F13E4C5 n5:271B57D9-363D-11E5-9242-09173F13E4C5 n5:271B57DA-363D-11E5-9242-09173F13E4C5 n5:271B57D7-363D-11E5-9242-09173F13E4C5 n5:271B57D8-363D-11E5-9242-09173F13E4C5 n5:271B57A4-363D-11E5-9242-09173F13E4C5 n5:271B57A5-363D-11E5-9242-09173F13E4C5 n5:271B57A2-363D-11E5-9242-09173F13E4C5 n5:271B57A3-363D-11E5-9242-09173F13E4C5 n5:271B57A0-363D-11E5-9242-09173F13E4C5 n5:271B57A1-363D-11E5-9242-09173F13E4C5 n5:271B579F-363D-11E5-9242-09173F13E4C5 n5:271B57AC-363D-11E5-9242-09173F13E4C5 n5:271B57AD-363D-11E5-9242-09173F13E4C5 n5:271B57AA-363D-11E5-9242-09173F13E4C5 n5:271B57AB-363D-11E5-9242-09173F13E4C5 n5:271B57A8-363D-11E5-9242-09173F13E4C5 n5:271B57A9-363D-11E5-9242-09173F13E4C5 n5:271B57A6-363D-11E5-9242-09173F13E4C5 n5:271B57A7-363D-11E5-9242-09173F13E4C5 n5:271B57CD-363D-11E5-9242-09173F13E4C5 n5:271B57CE-363D-11E5-9242-09173F13E4C5 n5:271B57B2-363D-11E5-9242-09173F13E4C5 n5:271B57B3-363D-11E5-9242-09173F13E4C5 n5:271B57B0-363D-11E5-9242-09173F13E4C5 n5:271B57B1-363D-11E5-9242-09173F13E4C5 n5:271B57AE-363D-11E5-9242-09173F13E4C5 n5:271B57AF-363D-11E5-9242-09173F13E4C5 n5:271B57B5-363D-11E5-9242-09173F13E4C5 n5:271B57B6-363D-11E5-9242-09173F13E4C5 n5:271B57B4-363D-11E5-9242-09173F13E4C5 n5:271B57BD-363D-11E5-9242-09173F13E4C5 n5:271B57BE-363D-11E5-9242-09173F13E4C5 n5:271B57BB-363D-11E5-9242-09173F13E4C5 n5:271B57BC-363D-11E5-9242-09173F13E4C5 n5:271B57B9-363D-11E5-9242-09173F13E4C5 n5:271B57BA-363D-11E5-9242-09173F13E4C5 n5:271B57B7-363D-11E5-9242-09173F13E4C5
n3:patent
n29:2268927 n29:6395294 n29:5976573
n3:synonym
Tiamcinolonum 9α-fluoro-16α-hydroxyprednisolone Triamcinolona 11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 9alpha-Fluoro-11beta,16alpha,17alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione Triamcinolonum 9alpha-Fluoro-16alpha-hydroxyprednisolone Fluoxyprednisolone
n3:toxicity
LD<sub>50</sub>=>500mg/kg (in rats)
n8:hasAHFSCode
n9:84-06-00 n9:68-04-00 n9:52-08-08
n3:mixture
n4:271B578C-363D-11E5-9242-09173F13E4C5 n4:271B5791-363D-11E5-9242-09173F13E4C5 n4:271B5792-363D-11E5-9242-09173F13E4C5 n4:271B578F-363D-11E5-9242-09173F13E4C5 n4:271B5790-363D-11E5-9242-09173F13E4C5 n4:271B578A-363D-11E5-9242-09173F13E4C5 n4:271B5795-363D-11E5-9242-09173F13E4C5 n4:271B5796-363D-11E5-9242-09173F13E4C5 n4:271B5793-363D-11E5-9242-09173F13E4C5 n4:271B5794-363D-11E5-9242-09173F13E4C5 n4:271B5799-363D-11E5-9242-09173F13E4C5 n4:271B5797-363D-11E5-9242-09173F13E4C5 n4:271B5798-363D-11E5-9242-09173F13E4C5 n4:271B578D-363D-11E5-9242-09173F13E4C5 n4:271B578E-363D-11E5-9242-09173F13E4C5 n4:271B578B-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
68%
n3:salt
n3:synthesisReference
Abu Alam, "Triamcinolone formulations and methods for their preparation and use." U.S. Patent US20040186084, issued September 23, 2004.
n23:hasConcept
n24:M0021894
foaf:page
n12:triamcinolone-spray.html n30:triamaer.htm n31:azm1044.shtml
n3:IUPAC-Name
n7:271B5851-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B5857-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B5856-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B5853-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B5854-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B5855-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B584F-363D-11E5-9242-09173F13E4C5 n7:271B5867-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B584D-363D-11E5-9242-09173F13E4C5 n7:271B5850-363D-11E5-9242-09173F13E4C5 n7:271B5869-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B584E-363D-11E5-9242-09173F13E4C5 n7:271B586A-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n10:R03BA06 n10:S01BA05 n10:A01AC01 n10:H02AB08 n10:C05AA12 n10:R01AD11 n10:D07XB02 n10:D07AB09
n3:H-Bond-Acceptor-Count
n7:271B585D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B585E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B5858-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B5859-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B585B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B585A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B585C-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapid absorption following oral administration
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
124-94-7
n3:category
n3:containedIn
n20:271B5818-363D-11E5-9242-09173F13E4C5 n20:271B5819-363D-11E5-9242-09173F13E4C5 n20:271B5816-363D-11E5-9242-09173F13E4C5 n20:271B5817-363D-11E5-9242-09173F13E4C5 n20:271B580D-363D-11E5-9242-09173F13E4C5 n20:271B580E-363D-11E5-9242-09173F13E4C5 n20:271B580B-363D-11E5-9242-09173F13E4C5 n20:271B580C-363D-11E5-9242-09173F13E4C5 n20:271B5809-363D-11E5-9242-09173F13E4C5 n20:271B580A-363D-11E5-9242-09173F13E4C5 n20:271B5808-363D-11E5-9242-09173F13E4C5 n20:271B5813-363D-11E5-9242-09173F13E4C5 n20:271B5814-363D-11E5-9242-09173F13E4C5 n20:271B5811-363D-11E5-9242-09173F13E4C5 n20:271B5812-363D-11E5-9242-09173F13E4C5 n20:271B580F-363D-11E5-9242-09173F13E4C5 n20:271B5810-363D-11E5-9242-09173F13E4C5 n20:271B581A-363D-11E5-9242-09173F13E4C5 n20:271B581B-363D-11E5-9242-09173F13E4C5 n20:271B5822-363D-11E5-9242-09173F13E4C5 n20:271B5823-363D-11E5-9242-09173F13E4C5 n20:271B5820-363D-11E5-9242-09173F13E4C5 n20:271B5821-363D-11E5-9242-09173F13E4C5 n20:271B581E-363D-11E5-9242-09173F13E4C5 n20:271B581F-363D-11E5-9242-09173F13E4C5 n20:271B581C-363D-11E5-9242-09173F13E4C5 n20:271B581D-363D-11E5-9242-09173F13E4C5 n20:271B582A-363D-11E5-9242-09173F13E4C5 n20:271B582B-363D-11E5-9242-09173F13E4C5 n20:271B5828-363D-11E5-9242-09173F13E4C5 n20:271B5829-363D-11E5-9242-09173F13E4C5 n20:271B5826-363D-11E5-9242-09173F13E4C5 n20:271B5827-363D-11E5-9242-09173F13E4C5 n20:271B5824-363D-11E5-9242-09173F13E4C5 n20:271B5825-363D-11E5-9242-09173F13E4C5 n20:271B5832-363D-11E5-9242-09173F13E4C5 n20:271B5833-363D-11E5-9242-09173F13E4C5 n20:271B5830-363D-11E5-9242-09173F13E4C5 n20:271B5831-363D-11E5-9242-09173F13E4C5 n20:271B582E-363D-11E5-9242-09173F13E4C5 n20:271B582F-363D-11E5-9242-09173F13E4C5 n20:271B582C-363D-11E5-9242-09173F13E4C5 n20:271B582D-363D-11E5-9242-09173F13E4C5 n20:271B5815-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n7:271B5863-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B5865-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B5866-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n7:271B5868-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B5862-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B5861-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B5864-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B5852-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n7:271B585F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B5860-363D-11E5-9242-09173F13E4C5